Latest Insider Transactions at Exact Sciences Corp (EXAS)
This section provides a real-time view of insider transactions for Exact Sciences Corp (EXAS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXACT SCIENCES CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXACT SCIENCES CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
6,832
-15.77%
|
$409,920
$60.55 P/Share
|
|
Feb 28
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
10,416
-0.86%
|
$635,376
$61.12 P/Share
|
|
Feb 28
2023
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
1,932
-20.46%
|
$117,852
$61.12 P/Share
|
|
Feb 28
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,924
-3.19%
|
$178,364
$61.12 P/Share
|
|
Feb 27
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,137
+12.63%
|
-
|
|
Feb 27
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
1,887
+7.43%
|
-
|
|
Feb 27
2023
|
Everett Cunningham Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,677
+22.57%
|
-
|
|
Feb 27
2023
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
9,194
+11.55%
|
-
|
|
Feb 27
2023
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+14.53%
|
-
|
|
Feb 27
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,492
+0.92%
|
-
|
|
Feb 27
2023
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+29.52%
|
-
|
|
Feb 27
2023
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
6,311
+3.38%
|
-
|
|
Feb 22
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,033
-1.2%
|
$64,046
$62.72 P/Share
|
|
Feb 22
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
398
-4.0%
|
$24,676
$62.72 P/Share
|
|
Feb 22
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
4,764
-0.4%
|
$295,368
$62.72 P/Share
|
|
Feb 22
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
2,710
-12.31%
|
$168,020
$62.72 P/Share
|
|
Feb 22
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,430
-5.55%
|
$88,660
$62.72 P/Share
|
|
Feb 22
2023
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
1,007
-3.5%
|
$62,434
$62.72 P/Share
|
|
Feb 22
2023
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
838
-13.25%
|
$51,956
$62.72 P/Share
|
|
Feb 21
2023
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+2.54%
|
-
|
|
Feb 21
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
865
+7.99%
|
-
|
|
Feb 21
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,374
+0.86%
|
-
|
|
Feb 21
2023
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
5,897
+12.43%
|
-
|
|
Feb 21
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,112
+10.78%
|
-
|
|
Feb 21
2023
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+7.25%
|
-
|
|
Feb 21
2023
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,729
+21.47%
|
-
|
|
Feb 16
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,076
-1.26%
|
$67,788
$63.91 P/Share
|
|
Feb 15
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
400
-4.21%
|
$26,000
$65.59 P/Share
|
|
Feb 15
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
954
-5.59%
|
$65,826
$69.59 P/Share
|
|
Feb 15
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
954
-1.11%
|
$62,010
$65.59 P/Share
|
|
Feb 15
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
14,617
-1.21%
|
$950,105
$65.59 P/Share
|
|
Feb 15
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,866
-7.61%
|
$121,290
$65.59 P/Share
|
|
Feb 15
2023
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
1,821
-6.43%
|
$118,365
$65.59 P/Share
|
|
Feb 14
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
883
+8.51%
|
-
|
|
Feb 14
2023
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,030
+10.63%
|
-
|
|
Feb 14
2023
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,030
+2.3%
|
-
|
|
Feb 14
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,132
+2.52%
|
-
|
|
Feb 14
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+13.94%
|
-
|
|
Feb 14
2023
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+12.3%
|
-
|
|
Feb 13
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
4,527
-0.38%
|
$289,728
$64.55 P/Share
|
|
Feb 13
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,158
-5.33%
|
$74,112
$64.55 P/Share
|
|
Feb 10
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,705
+0.82%
|
-
|
|
Feb 10
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,579
+10.62%
|
-
|
|
Feb 01
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,000
-1.18%
|
$67,000
$67.93 P/Share
|
|
Jan 13
2023
|
James Edward Doyle |
BUY
Exercise of conversion of derivative security
|
Direct |
5,477
+9.22%
|
$87,632
$16.52 P/Share
|
|
Jan 09
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,000
-1.16%
|
$60,000
$60.0 P/Share
|
|
Jan 03
2023
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
7,780
+24.22%
|
-
|
|
Oct 12
2022
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
16,872
-47.49%
|
$523,032
$31.37 P/Share
|
|
Oct 11
2022
|
Everett Cunningham Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,006
+39.53%
|
-
|
|
Aug 05
2022
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
984
-17.63%
|
$46,248
$47.12 P/Share
|